Cargando…

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence

The first subcutaneous (SC) formulation of infliximab CT-P13 has been authorized for the treatment of rheumatoid arthritis (RA) in Europe in 2019. Later, in 2020, approved indications were extended also to ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn’s disease (CD) and ulcerative co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iannone, Florenzo, Conti, Fabrizio, Cauli, Alberto, Farina, Alberto, Caporali, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167594/ https://www.ncbi.nlm.nih.gov/pubmed/35673354 http://dx.doi.org/10.2147/JIR.S240593

Ejemplares similares

Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial
por: Constantin, Arnaud, et al.
Publicado: (2022)

Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
por: Combe, Bernard, et al.
Publicado: (2021)

Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis
por: Vena, Gino Antonio, et al.
Publicado: (2018)

Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration
por: Bianchi, Gerolamo, et al.
Publicado: (2016)

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
por: Bobbio-Pallavicini, Francesca, et al.
Publicado: (2004)

Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium
por: Ceccarelli, Fulvia, et al.
Publicado: (2022)

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
por: Bray, Vance J., et al.
Publicado: (2018)

From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium”
por: Vitale, Antonio, et al.
Publicado: (2023)

Infliximab in the treatment of rheumatoid arthritis
por: Perdriger, A
Publicado: (2009)

Rheumatoid Arthritis from Easy to Complex Disease: From the “2022 GISEA International Symposium”
por: Perniola, Simone, et al.
Publicado: (2023)

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
por: Wakabayashi, Hiroki, et al.
Publicado: (2016)

How does infliximab work in rheumatoid arthritis?
por: Maini, Ravinder N, et al.
Publicado: (2002)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
por: Iannone, Claudia, et al.
Publicado: (2023)

Infliximab improves vascular stiffness in patients with rheumatoid arthritis
por: Wong, M, et al.
Publicado: (2008)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

A Case of Osteonecrosis of the Jaw in a Patient with Crohn’s Disease Treated with Infliximab
por: Favia, Gianfranco, et al.
Publicado: (2017)

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
por: Choy, Ernest, et al.
Publicado: (2019)

The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
por: Talotta, Rossella, et al.
Publicado: (2017)

Can Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis?
por: Humby, Frances Claire, et al.
Publicado: (2017)

Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis
por: Cacciapaglia, Fabio, et al.
Publicado: (2022)

A systematic review of infliximab in the treatment of early rheumatoid arthritis
por: Du Pan, Sophie Martin, et al.
Publicado: (2007)

The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
por: Dwivedi, Ravi C, et al.
Publicado: (2009)

The Draining Lymph Node in Rheumatoid Arthritis: Current Concepts and Research Perspectives
por: Benaglio, Francesca, et al.
Publicado: (2015)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
por: Cacciapaglia, Fabio, et al.
Publicado: (2018)

The Clinical Value of Autoantibodies in Rheumatoid Arthritis
por: Bugatti, Serena, et al.
Publicado: (2018)

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
por: Choy, Ernest, et al.
Publicado: (2018)

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
por: Choy, Ernest, et al.
Publicado: (2018)

Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries
por: Dominique, Alyssa, et al.
Publicado: (2023)

Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
por: Bertoldi, Ilaria, et al.
Publicado: (2021)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
por: Mulleman, Denis, et al.
Publicado: (2009)

Serum ghrelin in female patients with rheumatoid arthritis during treatment with infliximab
por: Magiera, Michal, et al.
Publicado: (2011)

Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab
por: Dénarié, Delphine, et al.
Publicado: (2017)

Casual effect of methotrexate+etanercept/infliximab on survival of patients with rheumatoid arthritis
por: Akhlaghi, Saeed, et al.
Publicado: (2019)

Recurrent and refractory corneal perforation secondary to rheumatoid arthritis treated with infliximab
por: Al Saleh, Ahmed, et al.
Publicado: (2021)

Performance of the 2010 Classification Criteria for Rheumatoid Arthritis: A Systematic Literature Review and a Meta-Analysis
por: Sakellariou, Garifallia, et al.
Publicado: (2013)

Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis
por: Cacciapaglia, Fabio, et al.
Publicado: (2016)

Radiomics to predict the mortality of patients with rheumatoid arthritis-associated interstitial lung disease: A proof-of-concept study
por: Venerito, Vincenzo, et al.
Publicado: (2023)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cjpmrbkhujlsn78ggf0cmigb4a